HSBC/CALL/EVOTEC/65/0.1/19.06.24 Share Price

Warrant

DE000TT8QEX8

Delayed Deutsche Boerse AG 19:35:38 23/05/2024 BST
0.001 EUR 0.00% Intraday chart for HSBC/CALL/EVOTEC/65/0.1/19.06.24

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
23/05/24 0.001 0.00%
22/05/24 0.001 0.00%
21/05/24 0.001 0.00%
20/05/24 0.001 0.00%
17/05/24 0.001 0.00%

Delayed Quote Deutsche Boerse AG

Last update May 23, 2024 at 07:35 pm

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying EVOTEC SE
Issuer HSBC
WKN TT8QEX
ISINDE000TT8QEX8
Date issued 01/10/2021
Strike 65
Maturity 19/06/2024 (27 Days)
Parity 10 : 1
Emission price 0.42
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.55
Lowest since issue 0.001
Delta0x
Omega 0.000000
Premium0x
Gearing54.03x
Moneyness 0.1413
Difference Strike 55.82
Difference Strike %+85.87%
Spread 0.032
Spread %96.97%
Intrinsic value 0.000000

Company Profile

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Sector
-
More about the company

Ratings for Evotec SE

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Evotec SE

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
9.605 EUR
Average target price
20.79 EUR
Spread / Average Target
+116.45%
Consensus